Frontiers
US$ 27.43
should glp-1 agonists be open access Mechanisms of action of GLP-1RA GLP-1 Receptor Agonists as Treatments
Description
Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial [press release]
The inclusion of these variables played a crucial role in controlling confounding factors within our study
Weve detected that JavaScript is disabled in this browser
In about 11 months, participants lost nearly a quarter of their body weight, an average of 58 lb, Jastreboff said during an interview
2017;153(12401250):e2
F., Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line
